{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-012417","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2025-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.279485+00:00","generated_at":"2026-05-17T09:34:51.292079+00:00","sec_items":["3.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Imunon regains Nasdaq minimum bid price compliance; trading continues uninterrupted","bullets":["Received Nasdaq Hearings Panel confirmation of regained compliance with $1.00 minimum bid price rule (Rule 5550(a)(2)).","Common stock (IMNN) to continue trading on Nasdaq Capital Market without interruption.","CEO notes recent 15% stock dividend and momentum from Phase 2 OVATION 2 trial for IMNN-001 in ovarian cancer.","Phase 3 OVATION 3 trial for IMNN-001 successfully initiated in North America."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-012417","json":"https://secwatch.observer/filing/0001493152-25-012417.json","markdown":"https://secwatch.observer/filing/0001493152-25-012417.md","text":"https://secwatch.observer/filing/0001493152-25-012417.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315225012417/0001493152-25-012417-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315225012417/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:34:51.292079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6a7430e1063d61f726e0fdddf5de18de4247daa5","claim":"Imunon, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"August 27, 2025, Imunon, Inc. (the “Company”) received a written notification from the Nasdaq Hearings Panel indicating that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the NASDAQ Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315225012417/0001493152-25-012417-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"compliance regained"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}